CHEMICAL HERITAGE FOUNDATION

PAUL S. ANDERSON

Transcript of an Interview Conducted by

James G. Traynham

at

Bristol-Myers Squibb Wilmington, Delaware

on

28 October 2002

(With Subsequent Corrections and Additions)

CHEMICAL HERITAGE FOUNDATION Oral History Program FINAL RELEASE FORM

This document contains my understanding and agreement with Chemical Heritage Foundation with respect to my participation in a tape-recorded interview conducted by

James G. Traynham on 28 October 2002

I have read the transcript supplied by Chemical Heritage Foundation.

- 1. The tapes, corrected transcript, photographs, and memorabilia (collectively called the "Work") will be maintained by Chemical Heritage Foundation and made available in accordance with general policies for research and other scholarly purposes.
- 2. I hereby grant, assign, and transfer to Chemical Heritage Foundation all right, title, and interest in the Work, including the literary rights and the copyright, except that I shall retain the right to copy, use, and publish the Work in part or in full until my death.
- 3. The manuscript may be read and the tape(s) heard by scholars approved by Chemical Heritage Foundation subject to the restrictions listed below. The scholar pledges not to quote from, cite, or reproduce by any means this material except with the written permission of Chemical Heritage Foundation.
 - I wish to place the conditions that I have checked below upon the use of this interview. I understand that Chemical Heritage Foundation will enforce my wishes until the time of my death, when any restrictions will be removed.

Please check one:

4.

No restrictions for access.

NOTE: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to obtain permission from Chemical Heritage Foundation, Philadelphia, PA.

b. _____

Semi-restricted access. (May view the Work. My permission required to quote, cite, or reproduce.)

c. _____

Restricted access. (My permission required to view the Work, quote, cite, or reproduce.)

This constitutes my entire and complete understanding.

(Signature) Dr. Paul S. Anderson

12/12/03 (Date)

This interview has been designated as Free Access.

One may view, quote from, cite, or reproduce the oral history with the permission of CHF.

Please note: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to credit CHF using the format below:

Paul S. Anderson, interview by James G. Traynham at Bristol-Myers Squibb, Wilmington, Delaware, 22 October 2002 (Philadelphia: Chemical Heritage Foundation, Oral History Transcript # 0266).



Chemical Heritage Foundation Oral History Program 315 Chestnut Street Philadelphia, Pennsylvania 19106



The Chemical Heritage Foundation (CHF) serves the community of the chemical and molecular sciences, and the wider public, by treasuring the past, educating the present, and inspiring the future. CHF maintains a world-class collection of materials that document the history and heritage of the chemical and molecular sciences, technologies, and industries; encourages research in CHF collections; and carries out a program of outreach and interpretation in order to advance an understanding of the role of the chemical and molecular sciences, technologies, and industries in shaping society.

PAUL S. ANDERSON

1938	Born in Concord, Vermont on 3 February
	Education
1959	B.S., chemistry, University of Vermont
1963	Ph.D., chemistry, University of New Hampshire
	Professional Experience
	MSDRL [Merck Sharp & Dohme Research Laboratories], West Point,
	Pennsylvania
1964-1969	Senior Research Chemist, Medicinal Chemistry Department
1969-1973	Research Fellow, Medicinal Chemistry Department
1973-1975	Senior Research Fellow, Medicinal Chemistry Department
1975-1979	Associate Director, Medicinal Chemistry Department
1979-1980	Senior Director, Medicinal Chemistry Department
1980-1988	Executive Director, Medicinal Chemistry Department
1988-1994	Vice President for Chemistry, West Point
1994-1998	DuPont-Merck Pharmaceutical Company, Wilmington, Delaware
1998-2001	DuPont Pharmaceutical Company, Wilmington, Delaware
	Senior Vice President for Chemical and Physical Sciences
	Bristol-Meyers Squibb Company, Wilmington, Delaware
2001-2002	Vice President, Drug Discovery

Honors

Philadelphia Section of the American Chemical Society Award
E.B. Herschberg Award for Important Discoveries in Medicinally
Active Substances (ACS)
D.Sc. (Honoris causa), University of Vermont
D.Sc. (Honoris causa), University of Montpelier
Lord Company Lecturer at Allegheny College
Regents Lecturer-University of California-Los Angeles, Department of Chemistry
Lambda Upsilon Award Lectureship, University of Nebraska, Department of Chemistry

1999	Commencement Speaker, College of Chemistry, University of California at Berkeley
2000	Robbins Lecturer at Pomona College
2001	Hurd Lecturer at Northwestern University
2001	American Chemical Society Award in Industrial Chemistry
2001	Doctor of Chemistry (Honoris causa), University of New
	Hampshire
2002	Perkin Medal, Society of Chemical Industry
2002	Edward Smissman Lecturer at the University of Kansas

ABSTRACT

Paul S. Anderson begins the interview with a discussion of his family and his childhood in Vermont. Though he was born in Concord, Vermont, in 1938, his father became the superintendent of Swainton, Vermont, schools soon after his son's birth, and so Anderson's family moved there. Paul Anderson attended Highgate High School, and went on to attend the University of Vermont for his undergraduate studies in chemistry. After receiving his B.S. in chemistry in 1959, Anderson attended the University of New Hampshire, where he earned his Ph.D. in chemistry in 1963. Following a brief post-doctoral fellowship with Jerrold Meinwald at Cornell University, Anderson accepted a senior research position at the Merck, Sharp & Dohme Research Laboratories. Over the next thirty years, Anderson advanced through the ranks of Merck leadership, eventually becoming the vice president for chemistry at their West Point facilities. In 1994, DuPont and Merck formed a joint-venture company, for which Anderson served as the vice president for the chemical and physical sciences. Then, in 1998, DuPont bought out Merck's half of the joint venture and made Anderson the senior vice president of his department for the newly formed DuPont Pharmaceuticals. When Bristol-Meyers Squibb bought DuPont Pharmaceuticals in 2001, Anderson continued with the company as the vice president of drug discovery. Anderson concludes his interview with his feelings about winning the Perkin Medal and the significance of federal funding for scientific research.

INTERVIEWER

James G. Traynham is a Professor of Chemistry at Louisiana State University, Baton Rouge. He holds a Ph.D. in organic chemistry from Northwestern University. He joined Louisiana State University in 1963 and served as chemistry department chairperson from 1968 to 1973. He was chairman of the American Chemical Society's Division of the History of Chemistry in 1988 and is currently councilor of the Baton Rouge section of the American Chemical Society. He was a member of the American Chemical Society's Joint-Board Council on Chemistry and Public Affairs, as well as a member of the Society's Committees on Science, Chemical Education, and Organic Chemistry Nomenclature. He has written over ninety publications, including a book on organic nomenclature and a book on the history of organic chemistry.

TABLE OF CONTENTS

- Childhood and Early Education Born in Concord, Vermont. Father's work in the Vermont school system. Attending Highgate High School. Initial interest in chemistry. Undergraduate education at the University of Vermont. Donald Gregg. Clinton Cook.
- Graduate School
 Graduate education at University of New Hampshire. Robert Lyle. Harold
 Iddles. Paul Jones. Lecturing at UNH. Introduction to medicinal chemistry.
- 9 Early Career

Post-doctoral fellowship with Jerrold Meinwald at Cornell University. Researching cockroaches. Harold Scheraga. Peter Debye. Joining Merck Laboratories. Working with Frank Robinson and Jim Sprague. Drug research at Merck. Gordon Gribble. Producing aromatic hydrocarbons. MK-108.

16 Moving to West Point

Ralph S. Hirschmann. Becoming the head of medicinal chemistry at West Point. P. Roy Vagelos becomes head of research at Merck. Management philosophy at West Point. Considering the mechanisms of action. Various drugs developed at Merck. The DuPont-Merck Pharmaceutical Company. The selling of Merck to Bristol-Meyers Squibb. The future of Bristol-Meyers.

24 Conclusion

Reflections on winning the Perkin Medal. The importance of federal investment in research. Serving as president of the American Chemical Society. Discussion of his wife and future goals.

28 Index

INDEX

A

Aggrastat, 18 Albany Molecular Research, 26 Albany, New York, 26 American Chemical Society [ACS], 8, 25-26 Analytical chemistry, 7, 22 Anderson, Paul S., 1 aunt, 2 father [Raymond E. Anderson], 1-5 graduate school experiences, 6 head of medicinal chemistry at West Point, 16 leadership philosophy, 17 mother [Inza], 1-2 on board of directors, 26 on scientific advisory boards, 26 sister, 1-2 succession plan, 19 undergraduate interests, 4 vice president at DuPont Merck Pharmaceuticals, 19 wife [Jane], 26 winning the Perkin Medal, 24 Animal rights activists, 12 Anthracenimine, 14-15 Anxiolytic activity, 14 Archer, Sidney, 11 Aromatic hydrocarbon system, 14 AstraZeneca Corporation, 23

B

Benzodiazepines, 14 Benzomorphan, 11 Benzynes, 14 Beta-blocker, 15 Biological systems, 8 *Blattaria*, 10 Bowdoin College, 9 Brain tissue studies, 15 Bristol-Meyers Squibb Corporation [BMS], 1, 20-23 Bush, Vannevar, 24

С

Calcium influx, 15 Carbonic/hydrase inhibitor. *See* Trusopt Cheletropic-elimination reaction, 14 *Chemical Engineering News*, 4 Chemical Heritage Foundation, 27 Color tests, 14 Computational science, 10 Concord, Vermont, 1 Cook, Clinton D., 5-7 Cornell University, 9-10, 26 Crixivan, 18

D

Dartmouth College, 14 Debye, Peter J.W., 10 Diasteriomers, 12 Diels-Alder chemistry, 14 Drug discovery, 17, 21-22, 24 DuPont Pharmaceuticals Company, 20-21 DuPont-Merck Pharmaceuticals Company, 19-20 Research Laboratories, 19

Е

E. I. DuPont de Nemours and Company, 19-20 Enantiomeric enhancement, 12 Essex Junction, Vermont, 1 Eyring, Henry, 10

F

Factional re-crystallization, 12 Friedman, Paul A., 19, 26

G

Glaucoma, 18
Glutamate-receptor antagonist, 15
N-methyl-D-asparate-type, 15
Gregg, Donald [Don], 5
Gribble, Gordon W., 14

H

High performance liquid chromatography [HPLC], 12 Highgate High School, 1 Hirschmann, Ralph S., 16 HIV protease inhibitor. *See* Crivixan HMG CoA reductase inhibitor. *See* Zocor Huff, Joel R., 19

I

Iddles, Harold A., 7-8 Incyte Pharmaceutical Company, 23 Inorganic chemistry, 7 Isoindoles, 14 Iverson, Leslie, 15

J

Jones, Paul, 7-8

K

Ketone, 5 Kim, [____.], 10 Kuivila, Henry, 7

L

Lake Champlain, 1 Lyle, Robert E. [Jr.], 7-9

M

May, Everett L., 11 Mechanism-of-action studies, 7, 13, 15, 18 Mechanistic-organic chemistry, 8 Medicinal chemistry, 5, 8, 16, 19, 22 Meinwald, Jerrold [Jerry], 9-10 Merck Sharpe & Dohme Reseach Labs, 9, 11-17, 19-22 MK-801, 15-16 radio-labeled analog of, 15 Molecular biology, 8 Molecules, 5, 7-10, 12-15, 18 cis, 10 small molecule kinetics, 10 transfused, 10 Morphinan, 11

Ν

Naphthalenimine, 14 National Historical Chemical Landmarks committee, 8 National Institutes of Health [NIH], 7, 9, 11 grant, 7 post-doctoral fellowship, 9 National Science Foundation [NSF], 5 grants, 5 New Hampshire, University of [UNH], 7-9, 26 Nitrogen-bridging system, 14 Non-nucleoside reverse transcriptase inhibitor. *See* Sustiva Nuclear magnetic resonance [NMR], 8, 12, 22

0

Organic chemistry, 5, 7, 10 Oxime, 5

P

P450 oxidation systems, 14 Perkin Medal, 1, 24 Pfizer, Inc., 26 Pharmaceutical industry, 15 Physical chemistry, 7 Physical-organic chemistry, 7, 10 Platelet aggregation. *See* Aggrastat PowerPoint, 8 Primate studies, 15 Proteins, 8, 10, 22 Pyrroles, 14

R

Racemic mixtures, 12 Radioligand displacement assay, 12 Rat-tail flick assay, 12 Robinson, Frank, 9, 11

S

Scheraga, Harold A, 10 Skolnick, Edward M. [Ed], 19 Sprague, James M. [Jim], 11 Sterling Research Institute, 11 Stroke, 15 Structural biology, 22 Sustiva, 18 Swanton, Vermont, 1-2

Т

Tetrafluorinated atomic ring, 14 Tosylates, 10 solvolysis of, 10 Trusopt, 18

U

Union High School, 2

V

Vagelos, P. Roy, 17-18 Vermont, University of, 3-7 College of Education, 3 College of Technology, 3 medical school, 4

W

West Point, Pennsylvania, 11 Whole animal experimentation, 12-14, 16 Widom, Benjamin, 10 Wilmington, Delaware, 1, 19, 21, 23 Winter, Charles, 12 World War II, 24

Z

Zocor, 18